CD30 | Tumour necrosis factor (TNF) receptor family | IUPHAR Guide to IMMUNOPHARMACOLOGY

Top ▲

CD30

Target id: 1877

Nomenclature: CD30

Systematic Nomenclature: TNFRSF8

Family: Tumour necrosis factor (TNF) receptor family

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: ON :     CD30 has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 595 01p36.22 TNFRSF8 TNF receptor superfamily member 8
Mouse 1 498 Tnfrsf8 tumor necrosis factor receptor superfamily, member 8
Rat 1 493 Tnfrsf8 TNF receptor superfamily member 8
Previous and Unofficial Names
CD30L receptor | tumor necrosis factor receptor superfamily, member 8 | tumor necrosis factor receptor superfamily
Database Links
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
UniProtKB
Wikipedia
Adaptor proteins (Human)
TRAF1, TRAF2, TRAF3, TRAF5

Download all structure-activity data for this target as a CSV file

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
AFM13 Hs Binding 8.0 pKd 1
pKd 8.0 (Kd 9.3x10-9 M) [1]
Description: Binding to CD30 determined in a competition assay on KARPAS-299 cells.
brentuximab vedotin Hs Inhibition - -
Other Binding Ligands
Key to terms and symbols Click column headers to sort
Ligand Sp. Action Affinity Units Reference
CD30 ligand {Sp: Human} Hs - - -

References

Show »

1. Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Kiprijanov S, Little M, Zhukovsky EA. (2014) A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs, 6 (3): 728-39. [PMID:24670809]

Contributors

Show »

How to cite this page

David MacEwan.
Tumour necrosis factor (TNF) receptor family: CD30. Last modified on 29/08/2018. Accessed on 16/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY, http://guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=1877.